Researchers have long wondered what causes people to lose muscle strength as they age and how exercise can prevent it from happening. Now, McMaster University researchers have discovered a key protein required to maintain muscle mass and muscle strength during aging. The team state that this finding means new and existing drugs targeting the protein may potentially be used to preserve muscle function during aging. The opensource study is published in the journal Cell Metabolism.
The current study found that the body’s fuel gauge, AMP-activated protein kinase (AMPK), is vital to slow muscle wasting with aging. The data findings showed that mice lacking AMPK in their muscle developed much greater muscle weakness than expected in a middle-aged mouse. Instead these mice, which were the equivalent of being just 50 years old, had muscles like that of an inactive 100-year-old.
Previous studies have shown that AMPK activity in muscle is ‘dialed down’ with aging in humans, so this may be an important cause of muscle loss during aging, hypothesize the team. Earlier research from the lab has shown that this metabolic switch is turned on with exercise as well as using commonly-prescribed medications such as metformin and salicylate (the active ingredient in Aspirin).
The team state that the AMPK pathway can be turned on with intense exercise and commonly-used Type 2 diabetes medications. They go on to add that by knowing that AMPK is vital for maintaining muscle mass with aging, they now plan to adapt exercise regimes and existing drugs to switch on AMPK in muscle more effectively. The researchers conclude that development of new selective activators of the AMPK pathway in muscle may also be effective to prevent muscle loss with aging.
Source: McMaster University
Michelle is a health industry veteran who taught and worked in the field before training as a science journalist.
Featured by numerous prestigious brands and publishers, she specializes in clinical trial innovation--expertise she gained while working in multiple positions within the private sector, the NHS, and Oxford University.